DEVELOPMENT AND VALIDATION OF GENERALIZABLE INTERPRETABLE AI BIOMARKERS TO PREDICT CLINICAL OUTCOMES IN BCG-TREATED PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER

被引：0
|
作者：
Lotan, Yair
Shah, Jay B.
Krishna, Viswesh
Launer, Bryn
Krishna, Vrishab
Shingi, Siddhant
Gordetsky, Jennifer
Gerald, Thomas
Shkolyar, Eugene
Hayne, Dickon
Redfern, Andrew
Spalding, Lisa
Stewart, Courtney
Narayanan, Vikram
Patil, Dattatreya
Packiam, Vignesh T.
Rajan, Anand
O'Donnell, Michael A.
Baekelandt, Loic
Fernandez, Mario I.
Schultz, Marcela
Hensley, Patrick J.
Allison, Derek B.
Taylor, John A.
Hamza, Ameer
Nimgaonkar, Vivek
Tiu, Ekin
Vaickus, Louis J.
Sonawane, Snehal
Miller, Daniel L.
Vrabac, Damir
Abuzeid, Waleed M.
Joshi, Anirudh
Chang, Sam S.
Williams, Stephen B.
机构：
来源：
JOURNAL OF UROLOGY | 2024年 / 211卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD27-12
引用
收藏
页码：E555 / E556
页数：2
相关论文
共 50 条
  • [11] Correlation between BMI, Diabetes Mellitus, and Outcomes in Patients Treated with BCG Immunotherapy for Non-Muscle Invasive Bladder Cancer
    Brooks, N. A.
    Matulay, J. T.
    Li, R.
    Kokorovic, A.
    Grossman, H. B.
    Shen, Y.
    Gao, J. J.
    Navai, N.
    Dinney, C. P. N.
    Kamat, A. M.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (12) : 902 - 903
  • [12] Re: Erdafitinib in BCG-treated High-risk Non-muscle- invasive Bladder Cancer
    Babjuk, Marko
    EUROPEAN UROLOGY, 2024, 86 (03) : 280 - 280
  • [13] Clinical Impact of Anti-Platelet Medication in Patients with Non-Muscle Invasive Bladder Cancer Treated with BCG Therapy
    Yuge, K.
    Kikuchi, E.
    Tanaka, N.
    Takeda, T.
    Matsumoto, K.
    Miyajima, A.
    Nakagawa, K.
    Oya, M.
    UROLOGY, 2012, 80 (03) : S218 - S218
  • [14] Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review
    He, Yuhui
    Wang, Ning
    Zhou, Xiaofeng
    Wang, Jianfeng
    Ding, Zhenshan
    Chen, Xing
    Deng, Yisen
    BMJ OPEN, 2018, 8 (04):
  • [15] Intravesical BCG therapy for non-muscle invasive bladder cancer
    Figurin, K. M.
    ONKOUROLOGIYA, 2012, 8 (01): : 14 - 22
  • [16] Re: Erdafitinib in BCG-Treated High-Risk Non-Muscle-Invasive Bladder Cancer
    Catto, J. W. F.
    Tran, B.
    Roupret, M.
    JOURNAL OF UROLOGY, 2024, 212 (05): : 779 - 779
  • [17] Diagnostic biomarkers in non-muscle invasive bladder cancer
    Izak Faiena
    Charles J. Rosser
    Karim Chamie
    Hideki Furuya
    World Journal of Urology, 2019, 37 : 2009 - 2016
  • [18] Diagnostic biomarkers in non-muscle invasive bladder cancer
    Faiena, Izak
    Rosser, Charles J.
    Chamie, Karim
    Furuya, Hideki
    WORLD JOURNAL OF UROLOGY, 2019, 37 (10) : 2009 - 2016
  • [19] A NOVEL NOMOGRAM TO PREDICT BCG RESPONSE IN PATIENTS WITH HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER
    Bree, Kelly
    Hensley, Patrick
    Brooks, Nathan
    Xiao, Lianchun
    Shen, Yu
    Navai, Neema
    Grossman, H. Barton
    Dinney, Colin
    Kamat, Ashish
    JOURNAL OF UROLOGY, 2021, 206 : E298 - E298
  • [20] Exploring the utility of a NGS multigene panel to predict BCG response in patients with non-muscle invasive bladder cancer
    Francesca, Belardinilli
    DE Meo, Michela
    DEL Giudice, Francesco
    Scornajenghi, Carlo maria
    Gazzaniga, Paola
    DE Berardinis, Ettore
    Marino, Luca
    Magliocca, Fabio massimo
    Chung, Benjamin inbeh
    Laszkiewicz, Jan
    Magri, Valentina
    Giannini, Giuseppe
    Nicolazzo, Chiara
    ONCOLOGY RESEARCH, 2025, 33 (03) : 723 - 731
12345